With COVID-19 increasing demand for testing supplies, Qiagen NV has emerged as a key player in the global response.
Sales of molecular testing and RNA extraction boosted the Dutch diagnostics maker’s first and second quarter 2020 revenues by 7% and 19%, respectively, compared to 2019.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?